CO005 / CellOrigin Biotech - LARVOL DELTA

The Dual Mechanism of Action of CO-005 Overcomes CD20 Resistance in Diffuse Large B-Cell Lymphoma. (PubMed, Immunotargets Ther) - "Despite the clinical success of anti-CD20 monoclonal antibodies (mAbs) such as rituximab in the treatment of B-cell lymphoma, therapeutic resistance and relapse remain significant challenges, particularly in tumors with low or heterogeneous CD20 expression resulting from antigen loss or phenotypic shifts. In vivo, CO-005 triggered robust intratumoral PCCD and remodelled the tumor microenvironment, characterized by increased macrophage and neutrophil infiltration, thereby enhancing innate immune activation and supporting a dual-mechanism mode of action that couples direct cancer cell killing with myeloid engagement. These findings position CO-005 as a mechanistically distinct and immunologically active therapeutic with the potential to overcome limitations of both CD20- and CD47-directed therapies and expand treatment options for B-cell lymphoma."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CALR • CD20 • SIRPA

Development of a novel bifunctional anti-CD47 fusion protein with improved efficacy and a favorable safety profile. (PubMed, Mol Cancer Ther) - "The ability of CO-005 to trigger strong PCCD while preserving conventional immune responses provides a novel and promising approach for CD47-targeted cancer therapy. Its favorable safety profile, observed in both in vitro and ex vivo studies, positions CO-005 as a promising candidate with potential therapeutic advantages over existing anti-CD47 treatments."

Journal • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • SIRPA

CO-005, a novel anti-CD47 fusion protein with improved safety and efficacy in Lymphoma therapies (SITC 2024) - "Background Anti-CD20 antibodies, such as rituximab, are crucial in the therapeutic strategies for nearly all subtypes of B-cell non-Hodgkin's lymphoma (NHL). Animals were kept under appropriate housing conditions with food and water ad libitum. All animal experiments were approved by the Norwegian Food Safety Authorities under identification number 29016."

Clinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • ANXA5 • SIRPA

CO-005, a novel anti-CD47 fusion protein with improved safety and efficacy in Lymphoma therapies (SITC 2024) - "Background Anti-CD20 antibodies, such as rituximab, are crucial in the therapeutic strategies for nearly all subtypes of B-cell non-Hodgkin's lymphoma (NHL). Animals were kept under appropriate housing conditions with food and water ad libitum. All animal experiments were approved by the Norwegian Food Safety Authorities under identification number 29016."

Clinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • ANXA5 • SIRPA

The importance of innovative design in enhancing the safety of the next generation anti-CD47 therapeutics (SITC 2024) - "CO-005 effectively targets and eradicates cancer cells similar to parental CO-001 but offers a significantly improved safety profile...Animals were kept under appropriate housing conditions with food and water ad libitum. All animal experiments were approved by the Norwegian Food Safety Authorities under identification number 29016."

Clinical • Oncology • ANXA5 • CD47 • SIRPA

The importance of innovative design in enhancing the safety of the next generation anti-CD47 therapeutics (SITC 2024) - "CO-005 effectively targets and eradicates cancer cells similar to parental CO-001 but offers a significantly improved safety profile...Animals were kept under appropriate housing conditions with food and water ad libitum. All animal experiments were approved by the Norwegian Food Safety Authorities under identification number 29016."

Clinical • Oncology • ANXA5 • CD47 • SIRPA